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Abstract
Background: Human studies of therapeutic angiogenesis, stem-cell, and progenitor-cell therapy have failed to demonstrate
consistent clinical benefit. Recent studies have shown that heparin increases circulating levels of anti-angiogenic peptides.
Given the widely prevalent use of heparin in percutaneous and surgical procedures including those performed as part of
studies examining the benefit of therapeutic angiogenesis and cell-based therapy, we compared the effects of
unfractionated heparin (UFH) on angiogenic peptides with those of bivalirudin, a relatively newer anticoagulant whose
effects on angiogenic peptides have not been studied.
Methodology/Principal Findings: We measured soluble fms-like tyrosine kinase-1 (sFLT1), placental growth factor (PlGF),
vascular endothelial growth factor (VEGF), and soluble Endoglin (sEng) serum levels by enzyme linked immunosorbent
assays (ELISA) in 16 patients undergoing elective percutaneous coronary intervention. Compared to baseline values, sFLT1
and PlGF levels increased by 26296313% and 253654%, respectively, within 30 minutes of UFH therapy (p,0.01 for both;
n=8). VEGF levels decreased by 93.265% in patients treated with UFH (p,0.01 versus baseline). No change in sEng levels
were observed after UFH therapy. No changes in sFLT1, PlGF, VEGF, or sEng levels were observed in any patients receiving
bivalirudin (n=8). To further explore the direct effect of anticoagulation on circulating angiogenic peptides, adult, male
wild-type mice received venous injections of clinically dosed UFH or bivalirudin. Compared to saline controls, sFLT1 and
PlGF levels increased by .500% (p,0.01, for both) and VEGF levels increased by 2216101% (p,0.05) 30 minutes after UFH
treatment. Bivalirudin had no effect on peptide levels. To study the cellular origin of peptides after anticoagulant therapy,
human coronary endothelial cells were treated with UFH and demonstrated increased sFLT1 and PlGF levels (ANOVA
p,0.01 for both) with reduced VEGF levels (ANOVA p,0.05). Bivalirudin had no effect on peptide levels in vitro.
Conclusions/Significance: Circulating levels of sFLT1, PlGF, and VEGF are significantly altered by UFH, while bivalirudin
therapy has no effect. These findings may have significant implications for clinical studies of therapeutic angiogenesis, stem-
cell and progenitor-cell therapy.
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Introduction
Since the discovery of vascular endothelial growth factor
(VEGF), therapeutic angiogenesis, stem-cell and progenitor-cell
therapy have attracted interest as an innovative approaches to
manage end-stage ischemic coronary and peripheral artery disease
[1], [2]. Although early, small-scale clinical studies demonstrated
the benefits of pro-angiogenic and anti-angiogenic treatments, and
underscored the potential effects of cyto-therapeutics largely by
using bone marrow-derived cells, subsequent randomized-con-
trolled trials have revealed mixed results with no large-scale data
showing efficacy with respect to clinical outcomes [1,2].
Heparin (unfractionated or low-molecular weight) is commonly
used for the treatment of coronary and peripheral artery disease,
especially in the settings of acute coronary syndromes (ACS) and
percutaneous coronary intervention (PCI). Recent data have
shown that heparin administration (in either unfractionated or
low-molecular weight form) increases levels of soluble fms-like
tyrosine kinase-1 (sFlt1) [3–6], a circulating splice variant of the
VEGF receptor 1 that is expressed by endothelial cells, vascular
smooth muscle cells, and monocytes [7,8]. sFlt1 binds to pro-
angiogenic factors including placental growth factor (PlGF),
VEGF-A and VEGF-B and sequesters those ligands from acting
on vascular cell surface receptors to promote angiogenesis and
vascular health [9]. Endoglin (CD105) is another membrane-
associated receptor that regulates the pro-angiogenic cytokine
transforming growth factor beta (TGFb1) [10]. The extracellular
domain of endoglin can also be proteolytically cleaved and
circulate as soluble Endoglin (sEng) [11]. Over the past decade,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34344several lines of evidence have suggested that sEng may also
negatively regulate angiogenesis [12–14].
Given the substantial use of heparin therapy in trials of
therapeutic angiogenesis and stem- and progenitor-cell therapy,
we compared the effects of unfractionated heparin (UFH) on
circulating levels of sFlt1, sEng, VEGF165 and PlGF with those of a
relatively new anticoagulant, bivalirudin, whose effects on
angiogenic peptides have not been explored.
Materials and Methods
Patient Population
In this prospective observational study, we enrolled 16 human
subjects presenting to Tufts Medical Center for elective PCI in the
setting of chronic stable angina as defined by American College of
Cardiology/American Heart Association guidelines [15]. All
subjects had angiographically confirmed significant coronary
artery disease, defined as a luminal narrowing greater than 70%,
requiring PCI. All subjects had baseline Thrombolysis in
Myocardial Infarction (TIMI) 3 flow in the coronary artery
targeted for PCI. Other inclusion criteria were as follows: age .18
years and ,90 years of age, sinus rhythm, and ability to provide
informed consent. Patients with heparin or contrast allergy;
hemodynamic or clinical instability; perceived interference with
standard clinical care of patients; unsuccessful reperfusion,
pregnancy, active or remote cancer, renal failure (estimated
glomerular filtration rate ,30 mL/min/1.73m
2) or liver trans-
aminases .2 times the upper limit of normal were excluded. All
eligible subjects who agreed to enroll received either UFH or
bivalirudin immediately before PCI as per standard dosing
protocols. Specifically, UFH was administered as a 60 units (U)/
kg bolus followed by a 10 U/kg/hour infusion. Bivalirudin was
dosed with a 0.75 mg/kg bolus and a 1.75 mg/kg/hour
continuous infusion. In all subjects, blood samples were obtained
via the arterial sheath immediately before anticoagulant admin-
istration and at 30-, and 60- minutes after anticoagulation. In 3
patients, additional blood samples were obtained at 6 and
24 hours from the administration of the anticoagulant.
All physicians were blinded to the results of the serum analysis.
Subjects received standard clinical care for elective PCI during
their hospitalization, including electrocardiograms and cardiac
biomarkers, and pharmacologic therapy including aspirin, clopi-
dogrel, HMG-CoA reductase inhibitors, beta-blockers, and
angiotensin converting enzyme-inhibitors, as clinically indicated.
No subjects in this study required the use of glycoprotein IIb/IIIa
inhibitors. Tufts Medical Center’s Institutional Review Board
approved this study. All subjects provided written informed
consent.
Circulating Angiogenic Peptides in vivo. Sixteen-week-
old, male, wild type C57/Bl6 mice received UFH or bivalirudin
via tail-vein injection. Control groups included mice receiving
normal saline or an inert polyanionic substance, dermatan sulfate
(DSO4) via tail-vein injection (n=4 per group). After 30 minutes
of treatment, serum samples were obtained from the inferior vena
cava.
Circulating Angiogenic Peptides in vitro. Human
coronary artery endothelial cells (HCAEC; Cell Applications
Inc., San Diego, CA, USA) were cultured to near confluence using
normal humidified tissue culture incubators with 5% CO2. For
anticoagulant stimulation studies, HCAECs were treated with
UFH, bivalirudin, or DSO4 for 30 minutes. Conditioned media
was then harvested for protein expression analysis.
Immunofluorescence. Human coronary artery endothelial
cells (HCAECs) were grown in uncoated 6-well culture plates,
rinsed in phosphate buffered saline (PBS) and fixed for 20 minutes
in 4% formaldehyde in PBS. Fixed cells were treated with the
anticoagulants using N-terminal- and C-terminal-specific Flt1
antibodies (C-17, sc-316, Santa Cruz Biotechnology, Santa Cruz,
Table 1. Subject Characteristics.
Characteristic Bivalirudin Heparin P value
(n=8) (n=8)
Clinical Characteristics
Age (years) 59.8612.2 62.8611.2 0.6
Sex (% men) 87.5 87.5 0.5
Race (% Caucasian) 87.5 100 0.2
Height (cm) 174.7610 173.8612.4 0.9
Weight (kg) 90613.4 101.7621.8 0.2
BSA (m2) 2.160.2 2.160.3 0.4
BMI 29.564.5 3.967.8 0.3
Past Medical History (%)
Hypertension 87.5 87.5 0.5
Diabetes mellitus 12.5 50 0.1
Active tobacco use 25 0 0.1
Coronary artery disease 25 62.5 0.04
Hypercholesterolemia 87.5 87.5 0.5
Myocardial infarction 12.5 12.5 0.5
Cerebrovascular disease 0 0 N/A
Peripheral vascular disease 25 0 0.1
Atrial fibrillation 0 12.5 0.2
Medications (%)
Aspirin 87.5 87.5 0.5
Clopidogrel 87.5 87.5 0.5
b-blocker 87.5 75 0.3
Angiotensin converting enzyme
inhibitor
12.5 62.5 0.02
Calcium channel blocker 12.5 12.5 0.5
Angiotensin-receptor-blocker 25 0 0.1
Aldosterone antagonist 0 0 N/A
Diuretic 0 0 N/A
Anti-lipid agent 87.5 87.5 0.5
Lab Values
Na+ 139.662.9 137.960.8 0.07
K+ 4.260.4 4.160.3 0.6
Cl- 106.163.5 103.860.9 0.06
CO2 2661.7 26.961.2 0.3
BUN 14.563.0 14.666.6 0.9
Creatinine 1.060.4 0.960.3 0.9
Glucose 111.6622.5 120.9624.1 0.3
White blood cells 7.461.7 8.162.0 0.6
Hemoglobin 14.161.2 12.561.3 0.05
Platelets 185.8622.8 188.6644.9 0.9
Prothrombin time 12.460.7 12.860.7 0.5
PTT 22.562.8 30.5613.2 0.2
INR 1.060.1 1.160.1 0.4
EF (%) 60.269.9 52.568.8 0.4
doi:10.1371/journal.pone.0034344.t001
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META confocal microscope system.
Biomarker Assays. Human blood samples were collected
using serum separator tubes and allowed to clot for 30 minutes
prior to centrifugation at 2000 g for 15 minutes. Serum samples
were immediately stored at 280uC. sFlt1, sEng, VEGF165 and
PlGF levels were measured in duplicate for each serum sample
using commercially available human quantitative sandwich
enzyme immunoassay kits (ELISA, R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instructions. Time to
completion of the human sFlt1 ELISA was 4.5 hours. For mouse
serum analysis, sFlt1, sEng, VEGF165 and PlGF levels were
measured using specific mouse ELISA kits (R&D Systems,
Minneapolis, MN, USA). The ELISA kit for human VEGF used
in our study detects only free VEGF, while the assay for mouse
VEGF detects total VEGF, both bound and free. For in vitro sFlt1
analysis, conditioned media from incubated HCAECs were
isolated, spun at 10,000 rpm for 5 minutes to remove cellular
debris, and then analyzed using a human sFlt1 ELISA kit (R&D
Systems, Minneapolis, MN, USA). Blinded observers performed
all biomarker assays.
Statistical Analysis
Data are expressed as mean6SE. Pair-wise comparisons were
made using analysis of variance (ANOVA) for continuous
variables. ANOVA with repeated measures (RM ANOVA)
examined change in outcome variables over time. For in vitro
data, 2-tailed t tests and 1-way ANOVA with a Bonferroni
correction for inter-group comparisons were used. All statistical
analyses were performed using SigmaStat Version 3.1 (Systat
Software, Inc., Chicago, IL) and Statistical Package for the Social
Sciences (SPSS, v16.0.1, SPSS, Inc., Chicago, IL). A P value of
,0.05 was used to denote significant difference.
Figure 1. Effects on angiogenic peptides of UFH (dotted lines) and bivalirudin (dashed lines) in human subjects undergoing PCI.
sFlt1 (A) and PlGF (B) were significantly increased by UFH but not bivalirudin, VEGF165 (C) was significantly decreased by UFH but not bivalirudin, and
sEng (D) was unchanged with both UFH and bivalirudin.
doi:10.1371/journal.pone.0034344.g001
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Subject Characteristics
Characteristics of the study groups are provided in Table 1. The
study groups were not different with respect to age, gender or race.
No significant differences in medication use or baseline laboratory
values were noted except for a higher number of patients receiving
angiotensin converting enzyme-inhibitor therapy prior to PCI in
the UFH group. All 16 subjects referred for elective PCI
underwent single-vessel coronary intervention with no difference
in the number of coronary stents deployed between the two groups
(1.2560.46 vs 1.62560.74, UFH versus bivalirudin, p=NS)
coronary stents. No intra-procedural complications occurred in
any subject. For subjects receiving UFH, a mean body weight of
90 kg was observed, yielding a mean bolus infusion of 5400 U
followed by a continuous infusion of 10 U/kg or 900 U/hr. The
mean time for procedures was 1.3 hours; thus, on average, each
patient received 6570 U of UFH total. For the bivalirudin group,
mean body weight was 100 kg, leading to a bolus of 75 mg and
175 mg/hr infusion. The mean time for procedures was 1.2 hours;
thus, on average, each patient received 110 mg of bivalirudin.
Differential Effects on Serum Angiogenic Peptide Levels
of Heparin and Bivalirudin in Human Subjects. Pre-
treatment levels of measured angiogenic peptides were not
different between the 2 groups (Figure 1). In patients receiving
UFH, serum sFLT1 and PlGF levels were significantly increased
within 30 minutes of UFH therapy (Figures 1A and 1B,
respectively, p,0.001 versus baseline for both; n=8). VEGF165
levels significantly decreased after 30 minutes of UFH therapy
(Figure 1C, p,0.001 versus baseline). No significant changes in
sEng levels were observed at 30 or 60 minutes after UFH therapy
(Figure 1D). In patients receiving bivalirudin, no change in serum
sFLT1, PGF, VEGF165 or sEng levels were observed. The assay
for human VEGF used in our study detects only free VEGF.
Therefore, any VEGF bound by heparin or by sFLT-1 will not be
detected. We believe the significant reduction in circulating VEGF
levels within 30 minutes of drug administration is due to the
combined effect of heparin and sFLT-1 binding to human VEGF
[16]. On the other hand, the assay for mouse VEGF detects total
VEGF, BOTH bound and free. For this reason, we were not
surprised to see that VEGF levels did not decrease. The increase in
circulating VEGF may be due to release of VEGF from interstitial
storage sites, such as skeletal muscle, by heparin treatment [17].
Figure 2. Time course of changes in sFlt1 (A), PlGF (B), VEGF165 (C) and sEng (D) with UFH and bivalirudin at baseline and 1, 6 and
24 hours after administration of anticoagulant. Note that levels of all angiogenic peptides revert to baseline levels by 24 hours with UFH and
levels do not change significantly over 24 hours with bivalirudin.
doi:10.1371/journal.pone.0034344.g002
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24 hours after Anticoagulant Therapy. To examine the
time course of alterations in serum angiogenic peptides after
anticoagulant therapy, serum was collected at the additional time-
points of 6 and 24 hours after PCI-related anticoagulation in 6
patients. sFlt1 and PlGF levels returned to baseline by 24 hours
after administration of UFH (Figure 2). VEGF165 levels were the
lowest at 1 hour, and returned to baseline levels by 24 hours. sEng
levels were not significantly changed up to 24 hours after UFH
therapy. In patients receiving bivalirudin, no change in serum
sFLT1, PlGF, VEGF165 or sEng levels were observed up to
24 hours after administration.
Differential Effects on Serum Angiogenic Peptide Levels
of Heparin and Bivalirudin in vivo in wild type C57/Bl6
mice. To explore the effects of UFH and bivalirudin in the
absence of atherosclerotic vascular disease and potential ischemia,
these anticoagulants were tested in a mouse model. As in our
human subjects, treatment with UFH for 30 minutes resulted in a
rapid and significant increase in mouse serum sFlt1 and PGF levels
(Figures 3A and 3B respectively, .500% increase, p,0.01, for
both) compared to normal saline controls (NS). UFH also
produced a modest but significant increase in mouse VEGF165
levels (Figure 3C, 221+101%, p,0.05). Treatment with DSO4 did
not influence sFlt1 or PlGF levels. VEGF165 levels were modestly
increased by DSO4 treatment. Bivalirudin treatment had no effect
on sFlt1, PlGF, and VEGF165 levels in the mouse. These data
support that the differential effects of UFH and bivalirudin on
serum angiogenic peptide levels are independent of the presence of
atherosclerotic disease.
Differential effects of Anticoagulants on Angiogenic
Peptide Release from Human Coronary Artery Endothelial
Cells. Endothelial cells are known to express sFlt1, PlGF,
Figure 3. Effects on angiogenic peptide levels of UFH and bivalirudin in vivo in wild type C57/Bl6 mice. Treatment with UFH for
30 minutes resulted in a rapid and significant increase in mouse serum sFlt1 (A) and PGF (B) levels (.500% increase, p,0.01, for both) compared to
normal saline vehicle. UFH also produced a modest but significant increase in mouse VEGF165 (C) levels (221+101%, p,0.05). Treatment with DSO4
did not influence sFlt1 or PlGF levels. VEGF165 levels were modestly increased by DSO4 treatment. Bivalirudin treatment had no effect on sFlt1, PlGF,
and VEGF165 levels. sEng (D) levels were mildly increased with vehicle, UFH, bivalirudin and DSO4, with no significant differences between the 4
treatments.
doi:10.1371/journal.pone.0034344.g003
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source of circulating peptides we stimulated HCAECs with various
concentrations of UFH and bivalirudin. Conditioned media levels
of sFLT1 and PlGF were significantly increased and VEGF165
levels reduced 30 minutes after treatment of HCAECs with UFH
(Figure 4A). These data are consistent with our clinical
observations and support the likelihood that these peptides are
released from the endothelium after treatment with UFH.
Since levels of sFLT1 are rapidly increased by UFH stimulation,
we next examined whether sFLT1 release from HCAECs is due to
cleavage from the cell surface. To test this hypothesis, immuno-
fluorescence microscopy was performed on anticoagulant-treated
HCAECs using an N-terminal- and a C-terminal-specific Flt1
antibody. Within 30 minutes of stimulation with UFH, we
observed a significant reduction in cell surface expression of the
sFlt1 N-terminal extracellular domain with no change in C-
terminal expression (Figure 5).
Treatment with bivalirudin had no effect on N-terminal or C-
terminal expression (Figure 5).
Discussion
The primary finding of our study is that administration of UFH
results in significant changes in circulating levels of angiogenic
peptides, while bivalirudin does not. sFlt1 and PlGF were
increased, while VEGF165 levels were decreased with UFH. We
demonstrated these differences in vivo using human subjects
undergoing PCI for coronary artery disease and healthy C57/
Bl6 mice, and in vitro using HCAECs. Since we recently
demonstrated that sFlt1 levels are elevated early after an acute
coronary occlusion [18], we used only patients with chronic stable
angina and also showed that the differential effects of UFH and
bivalirudin on serum angiogenic peptide levels are independent of
the presence of atherosclerotic disease.
The underlying mechanisms for the increase in sFlt1 levels after
heparin therapy are currently under investigation, although it is
believed that sFlt1, which is bound to heparan sulfate proteogly-
cans, is released with heparin treatment because of competitive
binding at its heparin-binding site [4]. The binding domain for
heparin has been previously characterized on the most potent
VEGF splice variant, VEGF165 [19]. The decrease in circulating
VEGF165 levels after administration of UFH is potentially due to
sequestration of VEGF into the extracellular matrix. We did
observe a more dramatic reduction in VEGF levels after UFH
treatment in patients as compared to HCAECs in vitro. There are
several potential explanations for this difference. First, endothelial
cells may not be the only source of circulating VEGF. Second, the
in vitro model does not fully recapitulate the effect of circulating
blood. Dissociation of VEGF from UFH or sFLT1 may occur in
vitro and limit the amount of free VEGF detected by the ELISA kit,
whereas the kinetics of UFH/VEGF or sFLT1/VEGF binding in
circulating blood may be different. Third, once heparin or sFLT1
binds to VEGF in vivo, these moieties may be sequestered by the
interstitium, which is not recapitulated by the in vitro system.
Therapeutic angiogenesis depends on the ability of angiogenic
factors to induce the formation of a collateral blood supply,
effectively bypassing a diseased coronary or peripheral artery.
Over 25 phase II or phase III clinical trials involving approxi-
mately 2500 patients with coronary and peripheral artery disease,
have assessed the efficacy of angiogenic cytokine protein and gene
therapy involving VEGFs, fibroblast growth factors (FGFs) and
other factors, with largely disappointing results showing no
substantial benefit of therapeutic angiogenesis for cardiovascular
disease [1]. Similarly, stem-cell and progenitor cell-based therapy
is proposed to repair ischemic and injured cardiac tissue through
mechanisms that include vascular repair, vasculogenesis and
angiogenesis [2]. Angiogenic growth factors and stem- and
progenitor-cells are frequently delivered via surgical or percuta-
neous procedures – either intracoronary or percutaneous intra-
myocardial injections – that often necessitate anticoagulant
therapy. Our findings suggest that the use of UFH in this setting
may limit the clinical utility of pro-angiogenic factors. Further-
more, the use of UFH may confound the ability to use angiogenic
peptides as clinical biomarkers.
The antiangiogenic properties of heparin in cancer have been
known for nearly 3 decades [20]. Heparin has previously been
shown to influence the angiogenic response to basic fibroblast
growth factor (bFGF) and other proangiogenic factors in cancer
[21]. Our findings of elevated sFlt1 levels with heparin raise the
possibility that heparin administration during procedures for
delivery of angiogenic growth factors and stem- and progenitor-
cells was anti-angiogenic, potentially contributing to the negative
results of clinical trials.
Bivalirudin is a relatively new antithrombotic therapy, which
acts through dual inhibition of thrombin and collagen-dependent
Figure 4. Levels of angiogenic peptides from human coronary artery endothelial cells treated with unfractionated heparin or
bivalirudin. A) Conditioned media levels of sFlt1, PlGF, VEGF and sEng 30 minutes after treatment with increasing concentrations of UFH. (p,0.05
vs control). B) Conditioned media levels of sFlt1, PlGF, VEGF and sEng 30 minutes after treatment with increasing concentrations of bivalirudin. No
differences were observed after treatment with bivalirudin.
doi:10.1371/journal.pone.0034344.g004
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bleeding outcomes and short-term outcomes when compared with
heparin [23,24]. Based on our findings that bivalirudin has no
effect on circulating angiogenic peptides, we propose that
bivalirudin be used as the anticoagulant during procedures for
delivery of angiogenic growth factors and stem- and progenitor-
cells in ongoing and future trials. Trials with negative results that
involved the use of heparin may need to be revisited in light of our
findings. Bivalirudin should also be preferred in the setting of
angiogenic therapy early during an acute myocardial infarction, at
which time sFlt1 levels are significantly elevated [18].
The choice of anticoagulant therapy may also carry significant
implications in other patient groups that require long-term
anticoagulation and in whom angiogenesis and sFlt1 levels are
relevant, such as cancer patients with venous thromboembolism,
pregnant women with premature labor, and patients undergoing
hemodialysis. Further research is necessary to understand all the
clinical ramifications of the potential anti-angiogenic properties of
heparin therapy.
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